Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: Development of a [3.3.0]-based series and other piperidine bioisosteres

  • Douglas J. Sheffler
  • , Michael T. Nedelovych
  • , Richard Williams
  • , Stephen C. Turner
  • , Brittany B. Duerk
  • , Megan R. Robbins
  • , Sataya B. Jadhav
  • , Colleen M. Niswender
  • , Carrie K. Jones
  • , P. Jeffrey Conn
  • , R. Nathan Daniels
  • , Craig W. Lindsley

Research output: Contribution to journalArticlepeer-review

Abstract

This Letter describes the development and SAR of a novel series of GlyT1 inhibitors derived from a scaffold hopping approach, in lieu of an HTS campaign, which provided intellectual property position. Members within this new [3.3.0]​-​based series, e.g. I, displayed excellent GlyT1 potency, selectivity, free fraction, and modest CNS penetration. Moreover, enantioselective GlyT1 inhibition was obsd., within this novel series and a no. of other piperidine bioisosteric cores.

Original languageEnglish
Pages (from-to)1062-1066
Number of pages5
JournalBioorganic and Medicinal Chemistry Letters
Volume24
Issue number4
Early online date13 Jan 2014
DOIs
Publication statusPublished - 15 Feb 2014

Fingerprint

Dive into the research topics of 'Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 2: Development of a [3.3.0]-based series and other piperidine bioisosteres'. Together they form a unique fingerprint.

Cite this